Please wait while the formulary information is being retrieved.
SYNAGIS (PALIVIZUMAB)
- Respiratory syncytial virus pneumonia prevention
100 mg/mL intramuscular solution
- Inject 15 mg/kg by intramuscular route once a month
50 mg/0.5 mL intramuscular solution
- Inject 15 mg/kg by intramuscular route once a month
Respiratory syncytial virus pneumonia prevention
- Inject 15 mg/kg by intramuscular route once a month
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Thrombocytopenic disorder
SYNAGIS (PALIVIZUMAB)
- Respiratory syncytial virus pneumonia prevention
- Acute bacterial otitis media
- Cyanosis
- Rhinitis
- Skin rash
- Upper respiratory infection
- Fever
More Frequent
Severe
Less Severe
- Abdominal herniation
- Abnormal hepatic function tests
- Cardiac arrhythmia
- Dyspnea
- Gastroenteritis
- Wheezing
- Cough
- Diarrhea
- Injection site sequelae
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Anaphylaxis
- Angioedema
- Hypersensitivity drug reaction
- Hypotension
- Hypotonia
- Thrombocytopenic disorder
- Urticaria
Less Severe
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Palivizumab
Safety and efficacy not established for treatment starting > 24 months of age.
- 2 Years – 18 Years
- Safety and efficacy not established for treatment starting > 24 months of age.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Palivizumab
Not indicated for adult use
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Not indicated for adult use |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory syncytial virus pneumonia prevention | |
| Z23 | Encounter for immunization |
| Z29.11 | Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSv) |
| Z29.89 | Encounter for other specified prophylactic measures |
| 0-9 | A-Z |
|---|---|
| Z23 | Encounter for immunization |
| Z29.11 | Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSv) |
| Z29.89 | Encounter for other specified prophylactic measures |
Formulary Reference Tool